Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$7,414,294

815 payments

Through program year 2025, Advanced Clinical Research is reported as receiving $7,414,294 in research payments, across 815 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,574 2
2024 Research $18,877 23
2023 Research $50,550 47
2022 Research $2,561,949 234
2021 Research $1,825,241 139
2020 Research $622,599 115
2019 Research $2,332,503 255

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $4,071,801 251 payments
  2. Novartis Pharmaceuticals Corporation $663,792 4 payments
  3. Romark Laboratories, LC $636,913 2 payments
  4. Allergan Inc. $448,552 43 payments
  5. Seqirus USA Inc $382,967 38 payments
  6. Radius Health, Inc. $286,814 147 payments
  7. Pfizer Inc. $248,602 96 payments
  8. Amgen Inc. $235,857 22 payments
  9. Merck Sharp & Dohme Corporation $194,532 49 payments
  10. Alnylam Pharmaceuticals Inc. $89,490 93 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $4,071,801 251 payments
  2. Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection $587,605 1 payment
  3. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $402,088 2 payments
  4. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $338,475 23 payments
  5. A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-Smts for the Treatment of Postmenopausal Women With Osteoporosis $286,814 147 payments
  6. A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $283,180 13 payments
  7. A 5 Year Prospective Study of An Anti Amyloid Therapy Cad106 Or Cnp520 in Slowing and Or Postponing Cognitive Decline in Asymptomatic Apoe 4 Homozygotes at Risk for Developing Alzheimers Disease Dementia $261,704 2 payments
  8. FOURIER OLE (Ph 4) $165,154 9 payments
  9. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $141,359 11 payments
  10. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $139,622 48 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record